Literature DB >> 27890631

Evasion of host immune defenses by human papillomavirus.

Joseph A Westrich1, Cody J Warren2, Dohun Pyeon3.   

Abstract

A majority of human papillomavirus (HPV) infections are asymptomatic and self-resolving in the absence of medical interventions. Various innate and adaptive immune responses, as well as physical barriers, have been implicated in controlling early HPV infections. However, if HPV overcomes these host immune defenses and establishes persistence in basal keratinocytes, it becomes very difficult for the host to eliminate the infection. The HPV oncoproteins E5, E6, and E7 are important in regulating host immune responses. These oncoproteins dysregulate gene expression, protein-protein interactions, posttranslational modifications, and cellular trafficking of critical host immune modulators. In addition to the HPV oncoproteins, sequence variation and dinucleotide depletion in papillomavirus genomes has been suggested as an alternative strategy for evasion of host immune defenses. Since anti-HPV host immune responses are also considered to be important for antitumor immunity, immune dysregulation by HPV during virus persistence may contribute to immune suppression essential for HPV-associated cancer progression. Here, we discuss cellular pathways dysregulated by HPV that allow the virus to evade various host immune defenses.
Copyright © 2016 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  APOBEC3; Adaptive immunity; DNA methylation; HPV; Histone modification; Immune evasion; Innate immunity; Oncogene; Papillomavirus; Restriction factor; Tumor virus; Virus evolution

Mesh:

Substances:

Year:  2016        PMID: 27890631      PMCID: PMC5325784          DOI: 10.1016/j.virusres.2016.11.023

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  181 in total

1.  An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22.

Authors:  Adam Jarmuz; Ann Chester; Jayne Bayliss; Jane Gisbourne; Ian Dunham; James Scott; Naveenan Navaratnam
Journal:  Genomics       Date:  2002-03       Impact factor: 5.736

2.  APOBEC3G DNA deaminase acts processively 3' --> 5' on single-stranded DNA.

Authors:  Linda Chelico; Phuong Pham; Peter Calabrese; Myron F Goodman
Journal:  Nat Struct Mol Biol       Date:  2006-04-23       Impact factor: 15.369

3.  Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo.

Authors:  Galina V Shurin; Robert L Ferris; Robert Ferris; Irina L Tourkova; Lori Perez; Anna Lokshin; Levent Balkir; Bobby Collins; Gurkamal S Chatta; Michael R Shurin
Journal:  J Immunol       Date:  2005-05-01       Impact factor: 5.422

4.  High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression.

Authors:  Jeanette Reiser; José Hurst; Maike Voges; Peter Krauss; Peter Münch; Thomas Iftner; Frank Stubenrauch
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

5.  Alpha-defensin HD5 inhibits furin cleavage of human papillomavirus 16 L2 to block infection.

Authors:  Mayim E Wiens; Jason G Smith
Journal:  J Virol       Date:  2014-12-24       Impact factor: 5.103

6.  Down-regulation of HLA class I antigen in human papillomavirus type 16 E7 expressing HaCaT cells: correlate with TAP-1 expression.

Authors:  Wei Li; Xiao-Mei Deng; Chuan-Xin Wang; Xiao Zhang; Gui-Xi Zheng; Jian Zhang; Jin-Bo Feng
Journal:  Int J Gynecol Cancer       Date:  2010-02       Impact factor: 3.437

7.  Human papillomavirus type 16 E7 oncoprotein associates with E2F6.

Authors:  Margaret E McLaughlin-Drubin; Kyung-Won Huh; Karl Münger
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

8.  Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C.

Authors:  Diane M Da Silva; Andrew W Woodham; Joseph G Skeate; Laurie K Rijkee; Julia R Taylor; Heike E Brand; Laila I Muderspach; Lynda D Roman; Annie A Yessaian; Huyen Q Pham; Koji Matsuo; Yvonne G Lin; Greg M McKee; Andres M Salazar; W Martin Kast
Journal:  Clin Immunol       Date:  2015-09-08       Impact factor: 3.969

9.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

10.  Human papillomavirus E7 oncoprotein increases production of the anti-inflammatory interleukin-18 binding protein in keratinocytes.

Authors:  Kathryn H Richards; Rosella Doble; Christopher W Wasson; Mohammed Haider; G Eric Blair; Miriam Wittmann; Andrew Macdonald
Journal:  J Virol       Date:  2014-01-29       Impact factor: 5.103

View more
  49 in total

1.  Regulation of the human papillomavirus type 16 late promoter by transcriptional elongation.

Authors:  William K Songock; Matthew L Scott; Jason M Bodily
Journal:  Virology       Date:  2017-04-24       Impact factor: 3.616

2.  Human Papillomavirus E7 Oncoprotein Subverts Host Innate Immunity via SUV39H1-Mediated Epigenetic Silencing of Immune Sensor Genes.

Authors:  Irene Lo Cigno; Federica Calati; Cinzia Borgogna; Alessandra Zevini; Silvia Albertini; Licia Martuscelli; Marco De Andrea; John Hiscott; Santo Landolfo; Marisa Gariglio
Journal:  J Virol       Date:  2020-01-31       Impact factor: 5.103

3.  Structure of High-Risk Papillomavirus 31 E6 Oncogenic Protein and Characterization of E6/E6AP/p53 Complex Formation.

Authors:  Marcel Chris Conrady; Irina Suarez; Gergö Gogl; Desiree Isabella Frecot; Anna Bonhoure; Camille Kostmann; Alexandra Cousido-Siah; André Mitschler; JiaWen Lim; Murielle Masson; Thomas Iftner; Frank Stubenrauch; Gilles Travé; Claudia Simon
Journal:  J Virol       Date:  2020-12-22       Impact factor: 5.103

4.  ERAP1 overexpression in HPV-induced malignancies: A possible novel immune evasion mechanism.

Authors:  Alina Steinbach; Jan Winter; Miriam Reuschenbach; Renata Blatnik; Alexandra Klevenz; Miriam Bertrand; Stephanie Hoppe; Magnus von Knebel Doeberitz; Agnieszka K Grabowska; Angelika B Riemer
Journal:  Oncoimmunology       Date:  2017-06-20       Impact factor: 8.110

Review 5.  Opportunities and challenges for human papillomavirus vaccination in cancer.

Authors:  Richard B S Roden; Peter L Stern
Journal:  Nat Rev Cancer       Date:  2018-03-02       Impact factor: 60.716

Review 6.  HPV-Related Papillary Lesions of the Oral Mucosa: A Review.

Authors:  Sasha J Betz
Journal:  Head Neck Pathol       Date:  2019-01-29

7.  Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model.

Authors:  Benjamin Y Jin; Tracy E Campbell; Lindsey M Draper; Sanja Stevanović; Bianca Weissbrich; Zhiya Yu; Nicholas P Restifo; Steven A Rosenberg; Cornelia L Trimble; Christian S Hinrichs
Journal:  JCI Insight       Date:  2018-04-19

Review 8.  WHIM Syndrome: from Pathogenesis Towards Personalized Medicine and Cure.

Authors:  Lauren E Heusinkveld; Shamik Majumdar; Ji-Liang Gao; David H McDermott; Philip M Murphy
Journal:  J Clin Immunol       Date:  2019-07-16       Impact factor: 8.317

9.  The Human Papillomavirus E6 Oncoprotein Targets USP15 and TRIM25 To Suppress RIG-I-Mediated Innate Immune Signaling.

Authors:  Cindy Chiang; Eva-Katharina Pauli; Jennifer Biryukov; Katharina F Feister; Melissa Meng; Elizabeth A White; Karl Münger; Peter M Howley; Craig Meyers; Michaela U Gack
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

Review 10.  Host cell restriction factors that limit transcription and replication of human papillomavirus.

Authors:  Samuel S Porter; Wesley H Stepp; James D Stamos; Alison A McBride
Journal:  Virus Res       Date:  2016-11-15       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.